Clinical Trials Logo

Bacterial Infections clinical trials

View clinical trials related to Bacterial Infections.

Filter by:

NCT ID: NCT00079989 Completed - Clinical trials for Gram-Negative Bacterial Infections

Study Evaluating Tigecycline in Selected Serious Infections Due to Resistant Gram-Negative Organisms

Start date: December 2003
Phase: Phase 3
Study type: Interventional

To evaluate the safety and efficacy of tigecycline in the treatment of subjects with selected serious infections caused by resistant gram-negative bacteria, eg, Acinetobacter baumannii, Enterobacter species, Klebsiella pneumoniae or other resistant gram-negative pathogens, for whom antibiotics have failed or who cannot tolerate other appropriate antimicrobial therapies. The primary efficacy endpoint will be the clinical response.

NCT ID: NCT00079976 Completed - Clinical trials for Gram-Positive Bacterial Infections

Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)

Start date: October 2003
Phase: Phase 3
Study type: Interventional

To evaluate the safety and efficacy of tigecycline in the treatment of selected serious infections caused by VRE. The primary efficacy endpoint will be the clinical response for all subjects.

NCT ID: NCT00062647 Completed - Clinical trials for Gram-Positive Bacterial Infections

Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia

ASSURE
Start date: August 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections.

NCT ID: NCT00044928 Completed - Clinical trials for Bacterial Infections

Study Evaluating Zosyn in Hospitalized Patients With Intra-abdominal Infection

Start date: July 2002
Phase: Phase 4
Study type: Interventional

A Phase IV, multicenter study of hospitalized patients with complicated intra-abdominal infection.

NCT ID: NCT00037050 Completed - Clinical trials for Bacterial Infections

Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria

Start date: April 2002
Phase: Phase 3
Study type: Interventional

This study will treat patients who have a short term central catheter that is thought to be infected with a specific bacteria (gram positive bacteria)

NCT ID: NCT00035854 Completed - Clinical trials for Bacterial Infections

New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)

Start date: February 2002
Phase: Phase 3
Study type: Interventional

This study will treat pediatric patients who have infections that are due to a specific bacteria (Vancomycin-Resistant Enterococcus)

NCT ID: NCT00035269 Completed - Clinical trials for Gram-positive Bacterial Infections

New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)

Start date: December 2001
Phase: Phase 3
Study type: Interventional

This study will treat patients who have a community-acquired pneumonia that is due to a specific bacteria (S. pneumoniae)

NCT ID: NCT00008853 Completed - Clinical trials for Bacterial Infections

Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines

Start date: n/a
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety and favorable immune response to an anti-streptococcal vaccine (a vaccine that treats a common bacterial infection) in healthy non-pregnant women. Group B Streptococcus (GBS) continues to be the single most frequent cause of life-threatening bacterial infection during the first 2 months of life. Further, GBS pregnancy-related morbidity afflicts more than 50,000 women annually in the US. Therefore, active immunization of women is an appealing strategy for the prevention of GBS disease in pregnant women and their infants during the first 3 months of infant life.

NCT ID: NCT00004829 Completed - Cystic Fibrosis Clinical Trials

Phase III Randomized Study of the Inhalation of Tobramycin in Patients With Cystic Fibrosis

Start date: June 1995
Phase: Phase 3
Study type: Interventional

OBJECTIVES: I. Determine the safety and efficacy of tobramycin in patients with cystic fibrosis who are chronically colonized with Pseudomonas aeruginosa. II. Determine whether this treatment produces tobramycin-resistant bacteria at a frequency different from the placebo group and whether the emergence of resistance is associated with a lack of clinical response.

NCT ID: NCT00004747 Completed - Cystic Fibrosis Clinical Trials

Phase II Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Mucoid Exopolysaccharide Pseudomonas Aeruginosa Immune Globulin for Cystic Fibrosis

Start date: July 1995
Phase: Phase 2
Study type: Interventional

OBJECTIVES: I. Assess the efficacy of monthly intravenous mucoid exopolysaccharide Pseudomonas aeruginosa immune globulin (MEP IGIV) given over 1 year in reducing the frequency of acute pulmonary exacerbation in patients with cystic fibrosis, mild to moderate pulmonary disease, and mucoid P. aeruginosa colonization. II. Assess the effect of MEP IGIV on FEV1, sputum density of mucoid P. aeruginosa, and the quality of life in these patients. III. Assess the safety of monthly MEP IGIV. IV. Assess population-based MEP IGIV pharmacokinetics during chronic therapy.